Scarica l'app Stockscreener
41.99
2.53%
-1.09
Dopo l'orario di chiusura:
41.98
-0.01
-0.02%
Precedente Chiudi:
$43.08
Aprire:
$42.64
Volume 24 ore:
67,715
Relative Volume:
1.01
Capitalizzazione di mercato:
$115.57M
Reddito:
$697.00K
Utile/perdita netta:
$-37.19M
Rapporto P/E:
-1.1139
EPS:
-37.6952
Flusso di cassa netto:
$-29.34M
1 W Prestazione:
-5.64%
1M Prestazione:
-23.81%
6M Prestazione:
-50.15%
1 anno Prestazione:
-92.27%
Intervallo 1D:
$41.98
$45.51
Intervallo di 1 settimana:
$41.53
$46.27
Portata 52W:
$7.26
$240.00
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
41.99 | 118.57M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Craig Hallum | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Spruce Biosciences (SPRB) gains 9.1% shareholder group led by AIGH - Stock Titan
Spruce Biosciences Welcomes Adrian Quartel as Chief Medical Officer - Contract Pharma
Spruce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Corporate Information (July 2026) - Minichart
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer - Investing News Network
Spruce Biosciences appoints Adrian Quartel as chief medical officer - Investing.com
Spruce Biosciences (NASDAQ: SPRB) names Adrian Quartel as chief medical officer - Stock Titan
SPRB|Spruce Biosciences Inc|Price:43.080|Chg%:-1.910 - TradingKey
Spruce Biosciences Inc (SPRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Spruce Biosciences Inc (SPRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spruce Biosciences Inc (SPRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spruce Biosciences Inc (SPRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SPRB|Spruce Biosciences Inc|Price:43.260|Chg%:-1.730 - TradingKey
Spruce Biosciences Inc (SPRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Certain Warrants of Spruce Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Certain Restrcied Stock Units of Spruce Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Spruce Biosciences (SPRB) Corporate presentation Summary - Quartr
Spruce Biosciences (SPRB) AGM 2026 Summary - Quartr
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme - The National Law Review
B. Riley Securities Initiates Spruce Biosciences(SPRB.US) With Buy Rating, Announces Target Price $160 - Moomoo
SPRB Initiates Coverage On B. Riley Securities -- Buy Rating Ass - GuruFocus
B.Riley initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com Nigeria
B.Riley initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com South Africa
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs - AOL.com
Form 4 Spruce Biosciences Inc For: 9 July By Investing.com - Investing.com Nigeria
Spruce Biosciences (SPRB) Leerink Global Healthcare Conference 2026 Summary - Quartr
Spruce Biosciences Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesPre-Earnings Setup - DonanımHaber
Spruce Biosciences (SPRB) CEO adds 266 shares through employee stock purchase plan - Stock Titan
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit - Business Wire
Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy - Seeking Alpha
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller - AOL.com
Spruce Biosciences (SPRB) Holds Steady Near Resistance After Flat SessionBuffered ETF - dars.gov.et
Price to book forward of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
Spruce Biosciences (SPRB) Joins Russell 3000 Index - GuruFocus
Spruce Biosciences Joins the Russell 3000® Index - BioSpace
Spruce Biosciences, Inc.(NasdaqCM:SPRB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 2500 Growth Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 2000 Index - marketscreener.com
Spruce Biosciences added to Russell 3000 index By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 2000 Value Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM:SPRB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Spruce Biosciences added to Russell 3000 index - Investing.com
Spruce Biosciences, Inc.(NasdaqCM:SPRB) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 3000E Growth Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell Microcap Index - marketscreener.com
ETFs Investing in Spruce Biosciences, Inc. Stocks - TradingView
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of Spruce Biosciences, Inc. – BOATS:SPRB - TradingView
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 3000E Value Benchmark - marketscreener.com
Spruce Biosciences Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock RallyEarnings Beat Streak - dars.gov.et
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):